Table 3 Relative proportions of susceptibility and resistance profiles from all uropathogens isolated from outpatients at Gulu regional hospital, northern Uganda (n = 82)
From: Antibiograms from community-acquired uropathogens in Gulu, northern Uganda - a cross-sectional study
Antibiotic (disc potency) | Sensitive (95% CI) | Intermediate (95% CI) | Total a(%) | Resistant (95% CI) |
|---|---|---|---|---|
Nitrofurantoin (50 μg) | 24 (19.5-40.4) | 20 (15.6-35.1) | 44 (53.7) | 38 (35.3-57.7) |
Nalidixic acid (30 μg) | 19 (14.7-33.8) | 20 (15.6-35.1) | 39 (47.6) | 43 (41.1-63.6) |
Cotrim.b (25/125 μg) | 12 (7.8-24.2) | 10 (6.0-21.3) | 22 (26.8) | 60 (56.2-82.4) |
Amoxicillin (10 μg) | 29 (25.1-46.7) | 11 (6.9-22.7) | 40 (48.8) | 42 (39.9-62.4) |
Amox-clav c (20/10 μg) | 39 (36.4-58.9) | 20 (15.6-35.1) | 59 (72.0) | 23 (18.7-39.1) |
Cephalexin (30 μg) | 26 (21.9-42.9) | 22 (17.6-37.8) | 48 (58.5) | 34 (30.7-52.9) |
Ciprofloxacin (5 μg) | 36 (33.0-55.3) | 6 (2.7-15.2) | 42 (51.2) | 40 (37.6-60.1) |
Levofloxacin (5 μg) | 44 (42.3-64.7) | 11 (6.9-22.7) | 55 (67.1) | 27 (22.9-44.2) |
Gentamicin (10 μg) | 62 (57.4-84.4) | 8 (4.3-18.3) | 70 (85.4) | 12 (7.8-24.2) |
Azithromycin (15 μg) | 26 (21.9-42.9) | 28 (24.0-45.4) | 54 (65.9) | 28 (24.0-45.4) |